secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950170-22-024675
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences Q3 net loss $35.1M; cash $289.1M, runway into 2025; Phase 3 PEAK trial started
--------------------------------------------------------------------------------

- Net loss $35.1M vs $19.1M YoY; R&D expense $29.9M (up from $14.8M) due to trials and team expansion.
- Cash & securities $289.1M as of Sep 30, 2022; cash runway expected into 2025.
- Phase 3 PEAK trial of bezuclastinib + sunitinib in second-line GIST patients initiated.
- Optimized bezuclastinib formulation shows >40% exposure improvement; potential patent protection to 2043.
- G&A expense $6.9M vs $5.0M YoY; non-cash stock comp included.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000095017022024675/0000950170-22-024675-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000095017022024675/cogt-20221114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024675

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer